Oct 3, 2012 by Brian Orelli, PhDStep Back From That Overnight Triple, SirSarepta skyrockets on phase 2 data, but investors should look at the risks too.
Oct 3, 2012 by Brian Orelli, PhDGood News, Just Not 13%-Pop Good NewsCell Therapeutics' investors overreact to an orphan drug designation.
Sep 28, 2012 by Brian Orelli, PhDDendreon Makes Progress, but Issues May LoomApproval of Provenge's European manufacturing plant are proceeding well, but the drug might run into the same issues across the pond.
Sep 28, 2012 by Brian Orelli, PhDXOMA Moves Ahead, but SlowlyXOMA starts phase 3 program for gevokizumab.
Sep 28, 2012 by Brian Orelli, PhDFDA Picks Up the Pace, Investors RejoiceCancer drugs benefiting from early FDA approvals.
Sep 27, 2012 by Brian Orelli, PhDTwin Orphan Drug NewsBioMarin produces good trial data for two orphan drug programs.
Sep 27, 2012 by Brian Orelli, PhDBigger, Better, Faster (but Behind)Achillion's second-generation hepatitis C drug looks good, but is behind.
Sep 25, 2012 by Brian Orelli, PhDFor This Stock, 2 Drugs Are Better Than 1Vertex pressed on with hepatitis C drug ALS-2200, but ALS-2158 is discontinued.
Sep 25, 2012 by Brian Orelli, PhDHow Many Pharmas Does It Take to Accelerate Drug Development?These companies are hoping to speed things up.
Sep 25, 2012 by Brian Orelli, PhD2 Drug Approvals and Shares Drop? That's Biotech!Regeneron gets two more approvals.
Sep 25, 2012 by Brian Orelli, PhDNo Quick Approval HereNavidea still needs to meet with the FDA before resubmitting its application for Lymphoseek.
Sep 21, 2012 by Brian Orelli, PhDEU Approval? Fat Chance!VIVUS says the EU is likely to reject its obesity drug.
Sep 20, 2012 by Brian Orelli, PhDIf You Can't Beat 'Em, Find an Indication Where They FailedSpectrum tries Zevalin as a maintenance therapy.
Sep 19, 2012 by Brian Orelli, PhDA Potential 36-Bagger BiotechAnthera starts its phase 3 program for blisibimod.
Sep 19, 2012 by Brian Orelli, PhDFDA Makes This Biotech Less RiskyARIAD's companion diagnostic doesn't require FDA approval.
Sep 18, 2012 by Brian Orelli, PhDIs This Good Drug Good Enough?Only a phase 3 trial of Threshold's T-302 can answer that.
